Skip to main
  1. Stocks
  2. Larimar Therapeutics Inc
  3. Forecast
LRMR

LRMR Stock Forecast & Price Target

LRMR Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Larimar Therapeutics is viewed favorably because nomlabofusp targets the root cause of Friedreich’s ataxia by delivering frataxin to mitochondria, and the clinical package shows sustained biomarker improvement alongside meaningful functional signals in a disease with no approved disease-modifying treatment. The regulatory setup also looks constructive after the rolling BLA submission was completed, with priority review still anticipated and a potential launch framework supported by earlier FDA designations and supportive pre-BLA feedback. Financially, the company reported $129M in cash and equivalents, plus $200.4M in cash, cash equivalents, and marketable securities at end-1Q26, with runway into late-2Q27 or 2Q27, though financing risk and possible dilution remain near-term overhangs.

Bears say

Larimar Therapeutics is highly exposed to regulatory and clinical setbacks, since accelerated approval may still require additional data, longer studies, or label limitations that could weaken commercialization. Its outlook is also constrained by a single-product dependence on nomlabofusp, so any safety issue or discontinuation would severely impair the pipeline and valuation. On top of that, competition from Biogen’s Skyclarys and other gene therapies, plus the likely need for additional external funding, creates meaningful execution and financing risk that could delay or terminate development programs.

LRMR has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

LRMR Analyst Forecast & Price Prediction

Get the latest LRMR stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LRMR

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Larimar Therapeutics Inc (LRMR) Forecast

Analysts have given LRMR a Buy based on their latest research and market trends.

According to 6 analysts, LRMR has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Larimar Therapeutics Inc (LRMR)


LRMR Analyst Forecast & Price Prediction

Get the latest LRMR stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LRMR

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LRMR stock data and trends